Immunic, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $99.5M
- Price
- $7.29
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.46%
- Volume
- 64.5K
About
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Quick stats
Shares outstanding13.6M
Computed float12.1M
Float / shares88.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001280776
Websitehttps://imux.com
AI Summary
AI-generated1/32
minorbullishclinical trial
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic announced four accepted abstracts on vidofludimus calcium for presentation at MSToronto2026, the joint ACTRIMS-ECTRIMS meeting, October 21-23, 2026, in Toronto.
New Phase 2 CALLIPER open-label extension data show disability outcomes favoring continuous treatment maintained through extension Week 48 with low discontinuation, plus preclinical evidence that Nurr1 is required for the drug's neuronal-survival effect.
The company's Phase 3 relapsing MS program remains on track for top-line data by end of 2026, making this a supportive precursor rather than a pivotal readout.
Red flags
- data are open-label extension and post-hoc/exploratory analyses, not pivotal Phase 3 results
- vidofludimus calcium is investigational and not approved by FDA or EMA